

10/582316

Express Mail No. EV668295389US

Date of deposit: June 8, 2006

SLR:dm 06/08/06 5585-68213-02 536280 RCD/P103734US

USPTO Rec'd PCT/PTO JUN 8 2006 PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Xin Lu and Elizabeth Slee

**Application No.** Currently unknown

**Filed:** Herewith

**Confirmation No.** Currently unknown

**For:** TUMOUR SUPPRESSOR PROTEIN

**Examiner:** Not yet assigned

**Art Unit:** Not yet assigned

**Attorney Reference No.** 5585-68213-02

MAIL STOP PCT  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 C.F.R. § 1.97(b)(2)**

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By   
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

cc: Docketing

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.D./ (08/27/2008)

SLR:dm 06/08/06 5585-68213-02 523176 RCD/P103734US

Express Mail No. EV668295389US

Date of Deposit: June 8, 2006

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	5585-68213-02
	Application Number	Currently unknown
	Filing Date	June 8, 2006
	First Named Inventor	Lu
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

**U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 02/12325 A2	02/14/2002	Ludwig Institute for Cancer Research
		WIPO	WO 03/000843 A2	01/03/2003	The Brigham & Women's Hospital, Inc.

**OTHER DOCUMENTS**

Examiner's Initials*	Cite No. (optional)	
		Database EMBL 'Online! Accession No. BC032298 (2002).
		Bergamaschi et al., "iASPP Oncoprotein is a Key Inhibitor of p53 Conserved from Worm to Human," <i>Nature Genetics</i> 33:162-167 (2003).
		Yang et al., "Identification of a Novel Inhibitor of Nuclear Factor- $\kappa$ B, RelA-Associated Inhibitor," <i>J. Biol. Chem.</i> 274:15662-15670 (1999).

<b>EXAMINER SIGNATURE:</b> /Minh Tam Davis/ (08/27/2008)	<b>DATE CONSIDERED:</b>
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	